261 related articles for article (PubMed ID: 1543370)
1. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
2. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Goldman ID; Matherly LH
NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
[TBL] [Abstract][Full Text] [Related]
3. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
4. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
5. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pharmacology of anticancer agents (Part 4). Antimetabolites (1)].
Nakamura T; Uchida M; Ueda T
Gan To Kagaku Ryoho; 1992 Feb; 19(2):265-76. PubMed ID: 1736842
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacologic rationale for high-dose methotrexate.
Jolivet J
NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
[TBL] [Abstract][Full Text] [Related]
8. Antifolate analogs: mechanism of action, analytical methodology, and clinical efficacy.
Fleisher M
Ther Drug Monit; 1993 Dec; 15(6):521-6. PubMed ID: 8122287
[TBL] [Abstract][Full Text] [Related]
9. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
Assaraf YG; Ifergan I; Kadry WN; Pinter RY
J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313
[TBL] [Abstract][Full Text] [Related]
10. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action.
Rosenthal GJ; Weigand GW; Germolec DR; Blank JA; Luster MI
J Immunol; 1988 Jul; 141(2):410-6. PubMed ID: 2968399
[TBL] [Abstract][Full Text] [Related]
11. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
13. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
15. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of anti-metabolites.
Peters GJ; Schornagel JH; Milano GA
Cancer Surv; 1993; 17():123-56. PubMed ID: 8137339
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Commun; 1989; 1(3):199-207. PubMed ID: 2700913
[TBL] [Abstract][Full Text] [Related]
18. [The metabolism of high-molecular-weight substances in cells and the effect of anticancer drugs].
Kanamaru R; Kakuta H; Sato T; Ishioka C; Konishi Y; Wakui A; Dei T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):837-44. PubMed ID: 3566294
[TBL] [Abstract][Full Text] [Related]
19. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
20. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]